Effects of low dose endotoxemia on endothelial progenitor cells in humans.
BACKGROUND
Endothelial progenitor cells (EPCs) are a specific subtype of hematopoietic stem cells that migrate from the bone marrow to the peripheral circulation where they contribute to the repair of injured endothelium and to the formation of new blood vessels. Levels of circulating EPCs have been investigated in different inflammatory disease states. However, data on circulating EPC levels and systemic inflammation remain scarce and contradictory.


OBJECTIVE
We investigated a putative relationship of low grade experimental endotoxemia to changes in circulating EPC levels.


METHODS
Randomized, double-blind, placebo-controlled parallel group trial in 36 healthy male volunteers. Thirty-two volunteers received 2 ng/kg LPS intravenously, the remaining four an equal volume of physiologic saline solution as placebo.


RESULTS
Endothelial progenitor cells showed a significant decrease over the observation period among the 32 subjects challenged with LPS (P<0.0001) and reached their nadir at 6 h, with a median decrease of 62% (interquartile range: 48-81%) compared with baseline levels. Circulating EPCs returned to values comparable to baseline 24 h after LPS challenge.


CONCLUSIONS
Infusion of 2 ng/kg LPS led to a significant decrease in peripheral EPCs. These results suggest that the early phase of acute inflammation is associated with a decrease in peripheral EPCs.
Mayr
F B
FB
Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Spiel
A O
AO
Leitner
J M
JM
Firbas
C
C
Sieghart
W
W
Jilma
B
B
D000328:Adult; D015992:Body Mass Index; D001854:Bone Marrow Cells / Q000378:metabolism; D003114:Colony-Forming Units Assay; D004311:Double-Blind Method; D042783:Endothelial Cells / Q000378:metabolism*; D019446:Endotoxemia / Q000150:complications*; D004731:Endotoxins / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D008070:Lipopolysaccharides / Q000378:metabolism; D008297:Male; D010919:Placebos; D013234:Stem Cells / Q000378:metabolism*; D016896:Treatment Outcome
D004731:Endotoxins; D008070:Lipopolysaccharides; D010919:Placebos